SynthesisInternational journal of colorectal disease2020
Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Qi Zhang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled itcites it